

## Arginine's role in nitric oxide synthase translation

Societies' gene pool influences individuals' traits

Acne drug isotretinoin retards macular degeneration

Fetal mRNA circulates in maternal blood

Disrupting settlements causes soil erosion

**Proceedings of the National Academy of Sciences of the United States of America** (ISSN-0027-8424) is published bi-weekly by the National Academy of Sciences.

**Correspondence:** PNAS, 500 Fifth Street, NW, NAS 340, Washington, DC 20001 USA (via U.S. postal service) or 2101 Constitution Avenue, NW, NAS 340, Washington, DC 20418 USA (via courier or express mail). E-mail: PNAS@nas.edu.

**Information for Authors:** See pp. xiv-xvi or www.pnas.org.

**Copyright:** Volumes 90-100, copyright © 1993-2003 by the National Academy of Sciences of the United States of America, all rights reserved. Volumes 1-89, copyright as a collective work only; author(s) retains copyright to individual articles.

**Requests for Permission:** Address requests to reproduce material published in Volumes 1-89 to the original author(s); send other requests by e-mail to PNASpermissions@nas.edu, fax 1-202-334-2739, or letter addressed to: PNAS Permissions Editor, 500 Fifth Street, NW, NAS 340, Washington, DC 20001 USA.

Please cite the exact material to be reprinted and state specifically where it will be used. **Photocopies:** PNAS is registered with the Copyright Clearance Center (CCC), 222 Rosewood Drive, Danvers, MA 01923 USA, fax 1-978-750-4470. Authorization to photocopy items for the internal or personal use of specific clients is granted by the National Academy of Sciences provided that the proper fee is paid directly to CCC. **Microforms:** Contact University Microfilms, Inc., P.O. Box 1346, Ann Arbor, MI 48106-1346 USA. This journal is printed on acid-free paper effective with Volume 84, Issue 1.

**Advertising:** PNAS Advertising Sales, 500 Fifth Street, NW, NAS 340, Washington, DC 20001 USA. Phone 1-202-334-2696, fax 1-202-334-2738, e-mail PNASads@nas.edu.

**Subscriptions:** Address correspondence to the PNAS Circulation Office, P.O. Box 631008, Baltimore, MD 21263 USA. For subscription help, e-mail subspnas@nas.edu, phone 1-202-334-1333, or visit www.pnas.org. Subscriptions are entered on a calendar-year basis. The 2003 rates for print plus online/online only are as follows—in the U.S.: student/postdoctoral, n.a./\$25; personal, \$250/\$125; institutional, \$1320/n.a.—U.S. by First Class at a surcharge of \$160—elsewhere (institutional includes expedited delivery): student/postdoctoral, n.a./\$25; personal, \$400/\$125; institutional, \$1650/n.a.—elsewhere by expedited delivery at a surcharge of \$300. **Exclusive Agent for Subscribers in Japan:** USACO Corporation, 17-12 Higashi-Azabu, 2-Chome, Minato-ku, Tokyo 106-0044, Japan. Phone 81 3 3505 3256, fax 81 3 3505 6282, e-mail agent@usaco.co.jp. **Change of Address:** Notify the Circulation Office 6 weeks in advance and list the old and new addresses. PNAS is not responsible for nonreceipt of issues because of an improper address, unless a change of address is on file. **Claims:** Requests for replacement copies will not be honored more than 60 days after the issue date for domestic subscribers and not more than 90 days after the issue date for foreign subscribers. Claims will not be honored for more than 2 issues per calendar year for the same subscriber. **Single Copies:** \$40 per issue in the U.S., \$50 elsewhere. **Canadian GST:** Registration Number R-133130880.

**Postmaster:** Send address changes to PNAS, 500 Fifth Street, NW, NAS 340, Washington, DC 20001 USA. Periodicals postage paid at Washington, DC, and additional mailing offices.

PNAS is available online at www.pnas.org. PRINTED IN THE USA

## President of the Academy

Bruce Alberts

## Editor-in-Chief

Nicholas R. Cozzarelli

## Associate Editor

Jack Halpern

## Editorial Board

Jan D. Achenbach  
James P. Allison  
Hans C. Andersen  
Frederick M. Ausubel  
Roger N. Beachy  
Joseph A. Beavo  
Michael L. Bender  
Stephen J. Benkovic  
May R. Berenbaum  
Bruce J. Berne  
Pamela J. Bjorkman  
Piet Borst  
David Botstein  
Patrick O. Brown  
Maurice B. Burg  
Charles R. Cantor  
Anthony Cerami  
Maarten J. Chrispeels  
Michael T. Clegg  
John M. Coffin  
Stanley N. Cohen  
James E. Dahlberg  
Carl de Boer  
Pietro V. De Camilli  
W. Ford Doolittle  
Herman N. Eisen  
W. G. Ernst  
Stanley Falkow  
Alan Fersht  
Christopher B. Field  
Richard A. Flavell  
Joseph G. Gall  
Joseph L. Goldstein  
Mark T. Groudine  
Philip C. Hanawalt  
Susan Hanson  
Henry C. Harpending  
Robert Haselkorn  
Peter M. Howley  
Tony Hunter  
Louis J. Ignarro  
L. L. Iversen  
Lily Y. Jan  
H. Ronald Kaback  
Richard V. Kadison

Samuel Karlin  
Richard M. Karp  
Thomas J. Kelly  
Robert P. Kirshner  
Alexander M. Klibanov  
John H. Law  
Simon A. Levin  
Michael S. Levine  
Michael Levitt  
George H. Lorimer  
Anthony P. Mahowald  
Philip W. Majerus  
Philippa Marrack  
Paul C. Martin  
Joan Massagué  
James L. McClelland  
John J. Mekalanos  
Douglas A. Melton  
Barbara J. Meyer  
Kiyoshi Mizuuchi  
Paul L. Modrich  
Peter B. Moore  
Newton E. Morton  
Bernard Moss  
Jeremy Nathans  
Masatoshi Nei  
Roger A. Nicoll  
Eric N. Olson  
Peter Palese  
Richard D. Palmiter  
Stanley B. Prusiner  
Charles M. Radding  
Marcus E. Raichle  
Kenneth N. Raymond  
Douglas C. Rees  
Jeffrey W. Roberts  
R. Michael Roberts  
John Ross  
Jeremy A. Sabloff  
Thomas J. Sargent  
Randy Schekman  
Matthew P. Scott  
Kai Simons  
William S. Sly  
Solomon H. Snyder  
Ralph M. Steinman  
Charles F. Stevens  
Harry L. Swinney  
G. David Tilman  
Robert Tjian  
Barry M. Trost  
Nicholas J. Turro  
Olke C. Uhlenbeck  
Inder M. Verma  
Peter K. Vogt

Kenneth W. Wachter  
David C. Ward  
Michael S. Waterman  
Susan R. Wessler

## Publisher

Kenneth R. Fulton

## Executive Editor

Diane M. Sullenberger

## Managing Editor

Bridget C. Coughlin

## Editorial Manager

Daniel H. Salsbury

## Production Manager

Jennifer L. Fleet

## Editorial Staff

Barbara A. Bacon  
Timothy Bauer  
Shanteika L. Booze  
Michael Campbell  
Mimi S. Clark  
Cassandra Foster  
B. Hope Hauptman  
Leikny V. Johnson  
Renita M. Johnson  
David Kasmier  
Mike Kolakoski  
Jaime Lees  
Tom Myers  
Andrew Pillifant  
Holli Porter  
Evan Redmon  
Donna L. Taylor  
Sarah B. Tegen  
Tanya D. Walker  
Daniel J. Whelan  
Reggie Wideman

## Business Manager

Paul R. Leider


## Business Staff

Mary Lou Aquilo  
Christina L. Colosimo  
Evelyn A. Gudger  
Julia A. Little  
Deborah Martin  
Sarah Frances  
Scarborough  
Latisha S. Watford

## Media Staff

Christen L. Brownlee  
Jill K. Locantore

STEENBOCK  
MEMORIAL LIBRARY  
APR 21 2003  
UW-MADISON



**Cover photograph:** Excessive nitric oxide generated by inducible nitric oxide synthase (iNOS) has been implicated in diseases including multiple sclerosis, Alzheimer's disease, and Parkinson's disease. iNOS expression is controlled by a translation mechanism involving the protein eIF2 $\alpha$ . Yellow/green-stained cells express an activated form of eIF2 $\alpha$  that leads to increased iNOS expression. Red-stained cells express only iNOS. The blue/purple stain represents cellular nuclei. See the article by Lee *et al.* on pages 4843–4848.

## From the Cover

- 4843 Arginine's role in nitric oxide synthase translation
- 4655 Societies' gene pool influences individuals' traits
- 4742 Acne drug isotretinoin retards macular degeneration
- 4748 Fetal mRNA circulates in maternal blood
- 4957 Disrupting settlements causes soil erosion

## Contents

### COMMENTARIES

- 4353 **Therapy for macular degeneration: Insights from acne**  
Janet R. Sparrow  
→ See companion article on page 4742
- 4355 **A silent bomb: The risk of anthrax as a weapon of mass destruction**  
G. F. Webb  
→ See companion article on page 4346 in issue 7 of volume 100
- 4357 **Evolution in a genetically heritable social environment**  
James M. Cheverud  
→ See companion article on page 4655
- 4360 **Placental mRNA in maternal plasma: Prospects for fetal screening**  
Malcolm A. Ferguson-Smith  
→ See companion article on page 4748
- 4363 **Radar breaks the fog: Insights into dorsoventral patterning in zebrafish**  
Thomas P. Wilm and Lilianna Solnica-Krezel  
→ See companion article on page 3315 in issue 6 of volume 100
- 4366 **How to interpret an ancient landscape**  
Vernon L. Scarborough  
→ See companion article on page 4957
- 4369 **What happens to genes in duplicated genomes**  
Elizabeth A. Kellogg  
→ See companion article on page 4649

### PHYSICAL SCIENCES

#### APPLIED MATHEMATICS

- 4372 **Assessing experimentally derived interactions in a small world**  
Debra S. Goldberg and Frederick P. Roth

#### CHEMISTRY

- 4377 **Evidence for direct carotenoid involvement in the regulation of photosynthetic light harvesting**  
Ying-Zhong Ma, Nancy E. Holt, Xiao-Ping Li, Krishna K. Niyogi, and Graham R. Fleming
- 4383 **Low T cell receptor expression and thermal fluctuations contribute to formation of dynamic multifocal synapses in thymocytes**  
Sung-Joo E. Lee, Yuko Hori, and Arup K. Chakraborty
- 4389 **Domain-selective small-molecule inhibitor of histone deacetylase 6 (HDAC6)-mediated tubulin deacetylation**  
Stephen J. Haggarty, Kathryn M. Koeller, Jason C. Wong, Christina M. Grozinger, and Stuart L. Schreiber

#### ENGINEERING

- 4395 **Microfluidics without microfabrication**  
Barry R. Lutz, Jian Chen, and Daniel T. Schwartz

#### GEOLOGY

- 4399 **A complex microbiota from snowball Earth times: Microfossils from the Neoproterozoic Kingston Peak Formation, Death Valley, USA**  
Frank A. Corsetti, Stanley M. Awramik, and David Pierce

## GEOPHYSICS

- 4405 **Stability of magnesiowüstite in Earth's lower mantle**  
Jung-Fu Lin, Dion L. Heinz, Ho-kwang Mao, Russell J. Hemley, James M. Devine, Jie Li, and Guoyin Shen

## MATHEMATICS

- 4409 **On conformally invariant differential operators in odd dimensions**  
Spyros Alexakis

## PHYSICS

- 4411 **Localization of denaturation bubbles in random DNA sequences**  
Terence Hwa, Enzo Marinari, Kim Sneppen, and Lei-han Tang
- 4417 **Buffed energy landscapes: Another solution to the kinetic paradoxes of protein folding**  
Steven S. Plotkin and Peter G. Wolynes

## BIOLOGICAL SCIENCES

### APPLIED BIOLOGICAL SCIENCES

- 4423 **Engineering the proteolytic specificity of activated protein C improves its pharmacological properties**  
David T. Berg, Bruce Gerlitz, Jing Shang, Tommy Smith, Paula Santa, Mark A. Richardson, Ken D. Kurz, Brian W. Grinnell, Ken Mace, and Bryan E. Jones
- 4429 **Peptide-mediated broad-spectrum plant resistance to tospoviruses**  
Christoph Rudolph, Peter H. Schreier, and Joachim F. Uhrig
- 4435 **Assembly of high-affinity insulin receptor agonists and antagonists from peptide building blocks**  
Lauge Schäffer, Renee E. Brissette, Jane C. Spetzler, Renuka C. Pillutla, Søren Østergaard, Michael Lennick, Jakob Brandt, Paul W. Fletcher, Gillian M. Danielsen, Ku-Chuan Hsiao, Asser S. Andersen, Olga Dedova, Ulla Ribell, Thomas Hoeg-Jensen, Per Hertz Hansen, Arthur J. Blume, Jan Markussen, and Neil I. Goldstein

### BIOCHEMISTRY

- 4372 **Assessing experimentally derived interactions in a small world**  
Debra S. Goldberg and Frederick P. Roth
- 4440 **3 $\beta$ -Acetoxyandrost-1,5-diene-17-ethylene ketal functions as a potent antiandrogen with marginal agonist activity**  
Hiroshi Miyamoto, Padma Marwah, Ashok Marwah, Henry Lardy, and Chawnshang Chang
- 4445 **Bioinformatic design of A-kinase anchoring protein-*in silico*: A potent and selective peptide antagonist of type II protein kinase A anchoring**  
Neal M. Alto, Scott H. Soderling, Naoto Hoshi, Lorene K. Langeberg, Rosa Fayos, Patricia A. Jennings, and John D. Scott
- 4451 **Structure of the GAT domain of human GGA1: A syntaxin amino-terminal domain fold in an endosomal trafficking adaptor**  
Silke Suer, Saurav Misra, Layla F. Saidi, and James H. Hurley

- 4457 **Isolation and identification of short nucleotide sequences that affect translation initiation in *Saccharomyces cerevisiae***  
Wei Zhou, Gerald M. Edelman, and Vincent P. Mauro

- 4463 **Amino acids determining enzyme-substrate specificity in prokaryotic and eukaryotic protein kinases**  
Lewyn Li, Eugene I. Shakhnovich, and Leonid A. Mirny

- 4469 **High-fidelity *in vivo* replication of DNA base shape mimics without Watson-Crick hydrogen bonds**  
James C. Delaney, Paul T. Henderson, Sandra A. Helquist, Juan C. Morales, John M. Essigmann, and Eric T. Kool

- 4474 **Phosphorylation of p47<sup>phox</sup> directs phox homology domain from SH3 domain toward phosphoinositides, leading to phagocyte NADPH oxidase activation**  
Tetsuro Ago, Futoshi Kuribayashi, Hidekazu Hiroaki, Ryu Takeya, Takashi Ito, Daisuke Kohda, and Hideki Sumimoto

- 4480 **Induced nucleotide specificity in a GTPase**  
Shu-ou Shan and Peter Walter

- 4486 **New components of the honey bee (*Apis mellifera* L.) queen retinue pheromone**  
Christopher I. Keeling, Keith N. Slessor, Heather A. Higo, and Mark L. Winston

- 4492 **Regulation of myotubularin-related (MTMR)2 phosphatidylinositol phosphatase by MTMR5, a catalytically inactive phosphatase**  
Soo-A Kim, Panayiotis O. Vacratsis, Ron Firestein, Michael L. Cleary, and Jack E. Dixon

- 4498 **L-SIGN (CD 209L) is a liver-specific capture receptor for hepatitis C virus**  
Jason P. Gardner, Robert J. Durso, Robert R. Arrigale, Gerald P. Donovan, Paul J. Maddon, Tatjana Dragic, and William C. Olson

- 4504 **Isothermal reactions for the amplification of oligonucleotides**  
Jeffrey Van Ness, Lori K. Van Ness, and David J. Galas

- 4510 **Protein trans-splicing in transgenic plant chloroplast: Reconstruction of herbicide resistance from split genes**  
Hang Gyeong Chin, Gun-Do Kim, Ivan Marin, Fana Mersha, Thomas C. Evans, Jr., Lixin Chen, Ming-Qun Xu, and Sriharsa Pradhan

### BIOPHYSICS

- 4411 **Localization of denaturation bubbles in random DNA sequences**  
Terence Hwa, Enzo Marinari, Kim Sneppen, and Lei-han Tang

- 4417 **Buffed energy landscapes: Another solution to the kinetic paradoxes of protein folding**  
Steven S. Plotkin and Peter G. Wolynes

- 4516 **Enhanced protein domain discovery by using language modeling techniques from speech recognition**  
Lachlan Coin, Alex Bateman, and Richard Durbin

- 4521 **Probing polymerization forces by using actin-propelled lipid vesicles**  
Arpita Upadhyaya, Jeffrey R. Chabot, Albina Andreeva, Azadeh Samadani, and Alexander van Oudenaarden

**4527 Conducting nanowires built by controlled self-assembly of amyloid fibers and selective metal deposition**  
Thomas Scheibel, Raghuvier Parthasarathy, George Sawicki, Xiao-Min Lin, Heinrich Jaeger, and Susan L. Lindquist

**4533 Signal sequence within FcγRIIA controls calcium wave propagation patterns: Apparent role in phagolysosome fusion**  
Randall G. Worth, Moo-Kyung Kim, Andrei L. Kindzelskii, Howard R. Petty, and Alan D. Schreiber

**4539 Structure and assembly of an augmented Sm-like archaeal protein 14-mer**  
Cameron Mura, Martin Phillips, Anna Kozhukhovskiy, and David Eisenberg

**4545 Site-specific contributions to the pH dependence of protein stability**  
Martin Tollinger, Karin A. Crowhurst, Lewis E. Kay, and Julie D. Forman-Kay

**4551 Frequency domain analysis of noise in autoregulated gene circuits**  
Michael L. Simpson, Chris D. Cox, and Gary S. Sayler

**4557 The hydration structure of guanidinium and thiocyanate ions: Implications for protein stability in aqueous solution**  
P. E. Mason, G. W. Neilson, C. E. Dempsey, A. C. Barnes, and J. M. Cruickshank

#### CELL BIOLOGY

**4389 Domain-selective small-molecule inhibitor of histone deacetylase 6 (HDAC6)-mediated tubulin deacetylation**  
Stephen J. Haggarty, Kathryn M. Koeller, Jason C. Wong, Christina M. Grozinger, and Stuart L. Schreiber

**4562 Filamin-A fragment localizes to the nucleus to regulate androgen receptor and coactivator functions**  
C. J. Loy, K. S. Sim, and E. L. Yong

**4568 C-terminal-binding protein corepresses epithelial and proapoptotic gene expression programs**  
Madeleine Grooteclaes, Quinn Deveraux, Jeffrey Hildebrand, Qinghong Zhang, Richard H. Goodman, and Steven M. Frisch

**4574 Processing, localization, and requirement of human separase for normal anaphase progression**  
Anton Chestukhin, Christian Pfeffer, Scott Milligan, James A. DeCaprio, and David Pellman

**4580 Hyaluronidase 2 negatively regulates RON receptor tyrosine kinase and mediates transformation of epithelial cells by jaagsiekte sheep retrovirus**  
Alla Danilovitch-Miagkova, Fuh-Mei Duh, Igor Kuzmin, Debora Angeloni, Shan-Lu Liu, A. Dusty Miller, and Michael I. Lerman

**4586 Mammalian Erv46 localizes to the endoplasmic reticulum–Golgi intermediate compartment and to cis-Golgi cisternae**  
Lelio Orci, Mariella Ravazzola, Gary J. Mack, Charles Barlowe, and Stefan Otte

**4592 The endomembrane requirement for cell surface repair**  
Paul L. McNeil, Katsuya Miyake, and Steven S. Vogel

**4598 MAN1 and emerin have overlapping function(s) essential for chromosome segregation and cell division in *Caenorhabditis elegans***  
Jun Liu, Kenneth K. Lee, Miriam Segura-Totten, Ester Neufeld, Katherine L. Wilson, and Yosef Gruenbaum

**4604 A GTP-driven motor moves proteins across the outer envelope of chloroplasts**  
Enrico Schleiff, Marko Jelic, and Jürgen Soll

**4610 Stabilization of β-catenin by a Wnt-independent mechanism regulates cardiomyocyte growth**  
Syed Haq, Ashour Michael, Michele Andreucci, Kausik Bhattacharya, Paolo Dotto, Brian Walters, James Woodgett, Heiko Kilter, and Thomas Force

#### DEVELOPMENTAL BIOLOGY

**4616 Identification of a small molecule inhibitor of the hedgehog signaling pathway: Effects on basal cell carcinoma-like lesions**

Juliet A. Williams, Oivin M. Guicherit, Beatrice I. Zaharian, Yin Xu, Ling Chai, Hynek Wichterle, Charlene Kon, Christine Gatchalian, Jeffery A. Porter, Lee L. Rubin, and Frank Y. Wang

**4622 Gatm, a creatine synthesis enzyme, is imprinted in mouse placenta**

Lisa L. Sandell, Xiao-Juan Guan, Robert Ingram, and Shirley M. Tilghman

**4628 Striking variation in the sex ratio of pups born to mice according to whether maternal diet is high in fat or carbohydrate**

Cheryl S. Rosenfeld, Kristie M. Grimm, Kimberly A. Livingston, Angela M. Brokman, William E. Lamberson, and R. Michael Roberts

**4633 An empty *Drosophila* stem cell niche reactivates the proliferation of ectopic cells**  
Toshie Kai and Allan Spradling

#### EVOLUTION

**4639 Positive selection in the egg receptor for abalone sperm lysin**

Blanca E. Galindo, Victor D. Vacquier, and Willie J. Swanson

**4644 Restoration of blood flow by using continuous perimuscular infiltration of plasmid DNA encoding subterranean mole rat *Spalax ehrenbergi* VEGF**  
Ariel Roguin, Aaron Avivi, Samy Nitecki, Irit Rubinstein, Nina S. Levy, Zaid A. Abassi, Murray B. Resnick, Orit Lache, Meira Melamed-Frank, Alma Joel, Aaron Hoffman, Eviatar Nevo, and Andrew P. Levy

**4649 Genes duplicated by polyploidy show unequal contributions to the transcriptome and organ-specific reciprocal silencing**

Keith L. Adams, Richard Cronn, Ryan Percifield, and Jonathan F. Wendel

→ See commentary on page 4369

**4655 Genetic architecture and evolutionary constraint when the environment contains genes**

Jason B. Wolf

→ See commentary on page 4357

**4661 Majority of divergence between closely related DNA samples is due to indels**

Roy J. Britten, Lee Rowen, John Williams, and R. Andrew Cameron

## GENETICS

- 4666 Expression profiling reveals altered satellite cell numbers and glycolytic enzyme transcription in nemaline myopathy muscle**  
 Despina Sanoudou, Judith N. Haslett, Alvin T. Kho, Shaoqiang Guo, Hanna T. Gazda, Steven A. Greenberg, Hart G. W. Lidov, Isaac S. Kohane, Louis M. Kunkel, and Alan H. Beggs
- 4672 Role of SeqA and Dam in *Escherichia coli* gene expression: A global/microarray analysis**  
 Anders Løbner-Olesen, Martin G. Marinus, and Flemming G. Hansen
- 4678 Essential *Bacillus subtilis* genes**  
 K. Kobayashi, S. D. Ehrlich, A. Albertini, G. Amati, K. K. Andersen, M. Arnaud, K. Asai, S. Ashikaga, S. Aymerich, P. Bessieres, F. Boland, S. C. Brignell, S. Bron, K. Bunai, J. Chapuis, L. C. Christiansen, A. Danchin, M. Débarbouillé, E. Dervyn, E. Deuerling, K. Devine, S. K. Devine, O. Dreesen, J. Errington, S. Fillinger, S. J. Foster, Y. Fujita, A. Galizzi, R. Gardan, C. Eschevins, T. Fukushima, K. Haga, C. R. Harwood, M. Hecker, D. Hosoya, M. F. Hullo, H. Kakeshita, D. Karamata, Y. Kasahara, F. Kawamura, K. Koga, P. Koski, R. Kuwana, D. Imamura, M. Ishimaru, S. Ishikawa, I. Ishio, D. Le Coq, A. Masson, C. Mauël, R. Meima, R. P. Mellado, A. Moir, S. Moriya, E. Nagakawa, H. Nanamiya, S. Nakai, P. Nygaard, M. Ogura, T. Ohanan, M. O'Reilly, M. O'Rourke, Z. Pragai, H. M. Pooley, G. Rapoport, J. P. Rawlins, L. A. Rivas, C. Rivolta, A. Sadaie, Y. Sadaie, M. Sarvas, T. Sato, H. H. Saxild, E. Scanlan, W. Schumann, J. F. M. L. Seegers, J. Sekiguchi, A. Sekowska, S. J. Sörör, M. Simon, P. Stragier, R. Studer, H. Takamatsu, T. Tanaka, M. Takeuchi, H. B. Thomaides, V. Vagner, J. M. van Dijl, K. Watabe, A. Wipat, H. Yamamoto, M. Yamamoto, Y. Yamamoto, K. Yamane, K. Yata, K. Yoshida, H. Yoshikawa, U. Zuber, and N. Ogasawara
- 4684 Epigenetic abnormalities associated with a chromosome 18(q21-q22) inversion and a Gilles de la Tourette syndrome phenotype**  
 Matthew W. State, John M. Grealley, Adam Cuker, Peter N. Bowers, Octavian Henegariu, Thomas M. Morgan, Murat Gunel, Michael DiLuna, Robert A. King, Carol Nelson, Abigail Donovan, George M. Anderson, James F. Leckman, Trevor Hawkins, David L. Pauls, Richard P. Lifton, and David C. Ward
- 4690  $\alpha$ -Synuclein maps to a quantitative trait locus for alcohol preference and is differentially expressed in alcohol-preferring and -nonpreferring rats**  
 Tiebing Liang, John Spence, Lixiang Liu, Wendy N. Strother, Hwai Wen Chang, Julie A. Ellison, Lawrence Lumeng, Ting-Kai Li, Tatiana Foroud, and Lucinda G. Carr
- 4696 *Drosophila* p53 preserves genomic stability by regulating cell death**  
 Naoko Sogame, Misoo Kim, and John M. Abrams
- 4702 Comprehensive sampling of gene expression in human cell lines with massively parallel signature sequencing**  
 C. Victor Jongeneel, Christian Iseli, Brian J. Stevenson, Gregory J. Riggins, Anita Lal, Alan Mackay, Robert A. Harris, Michael J. O'Hare, A. Munro Neville, Andrew J. G. Simpson, and Robert L. Strausberg
- 4706 Closing the loop: The PmrA/PmrB two-component system negatively controls expression of its posttranscriptional activator PmrD**  
 Akinori Kato, Tammy Latifi, and Eduardo A. Groisman

## IMMUNOLOGY

- 4383 Low T cell receptor expression and thermal fluctuations contribute to formation of dynamic multifocal synapses in thymocytes**  
 Sung-Joo E. Lee, Yuko Hori, and Arup K. Chakraborty
- 4712 Biologic activity of cytotoxic T lymphocyte-associated antigen 4 antibody blockade in previously vaccinated metastatic melanoma and ovarian carcinoma patients**  
 F. Stephen Hodi, Martin C. Mihm, Robert J. Soiffer, Frank G. Haluska, Marcus Butler, Michael V. Seiden, Thomas Davis, Rochele Henry-Spires, Suzanne MacRae, Ann Willman, Robert Padera, Michael T. Jaklitsch, Sridhar Shankar, Teresa C. Chen, Alan Korman, James P. Allison, and Glenn Dranoff
- 4718 Solution structure of a functionally active fragment of decay-accelerating factor**  
 Stanislava Uhrinova, Feng Lin, Graeme Ball, Krystyna Bromek, Dusan Uhrin, M. Edward Medof, and Paul N. Barlow
- 4724 IL-15R $\alpha$  expression on CD8<sup>+</sup> T cells is dispensable for T cell memory**  
 Patrick R. Burkett, Rima Koka, Marcia Chien, Sophia Chai, Faye Chan, Averil Ma, and David L. Boone
- 4730 Epstein-Barr virus-infected B cells expanding in germinal centers of infectious mononucleosis patients do not participate in the germinal center reaction**  
 Julia Kurth, Martin-Leo Hansmann, Klaus Rajewsky, and Ralf Küppers

## MEDICAL SCIENCES

- 4736 Inhibition of plaque neovascularization reduces macrophage accumulation and progression of advanced atherosclerosis**  
 Karen S. Moulton, Khashayar Vakili, David Zurakowski, Mohsin Soliman, Catherine Butterfield, Erik Sylvén, Kin-Ming Lo, Stephen Gillies, Kashi Javaherian, and Judah Folkman
- 4742 Treatment with isotretinoin inhibits lipofuscin accumulation in a mouse model of recessive Stargardt's macular degeneration**  
 Roxana A. Radu, Nathan L. Mata, Steven Nusinowitz, Xinran Liu, Paul A. Sieving, and Gabriel H. Travis  
 → See commentary on page 4353
- 4748 mRNA of placental origin is readily detectable in maternal plasma**  
 Enders K. O. Ng, Nancy B. Y. Tsui, Tze K. Lau, Tse N. Leung, Rossa W. K. Chiu, Nirmal S. Panesar, Lydia C. W. Lit, Kam-Wing Chan, and Y. M. Dennis Lo  
 → See commentary on page 4360
- 4754 Smooth muscle cells in human coronary atherosclerosis can originate from cells administered at marrow transplantation**  
 Noel M. Caplice, T. Jared Bunch, Paul G. Stalboerger, Shaohua Wang, David Simper, Dylan V. Miller, Stephen J. Russell, Mark R. Litzow, and William D. Edwards
- 4760 Identification of Down's syndrome critical locus gene *SMI2-s* as a drug therapy target for solid tumors**  
 Maurice Phil DeYoung, Matthew Tress, and Ramaswamy Narayanan

- 4766 Human tumstatin and human endostatin exhibit distinct antiangiogenic activities mediated by  $\alpha v\beta 3$  and  $\alpha 5\beta 1$  integrins**  
Akulapalli Sudhakar, Hikaru Sugimoto, Changqing Yang, Julie Lively, Michael Zeisberg, and Raghu Kalluri

- 4772 The cyclopentenone 15-deoxy- $\Delta^{12,14}$ -prostaglandin  $J_2$  binds to and activates H-Ras**  
José Luis Oliva, Dolores Pérez-Sala, Antonio Castrillo, Natalia Martínez, F. Javier Cañada, Lisardo Boscá, and José M. Rojas

- 4778 Evidence that the retroviral DNA integration process triggers an ATR-dependent DNA damage response**  
René Daniel, Gary Kao, Konstantin Taganov, James G. Greger, Olga Favorova, George Merkel, Tim J. Yen, Richard A. Katz, and Anna Marie Skalka

- 4784 Abbreviated incubation times for human prions in mice expressing a chimeric mouse-human prion protein transgene**  
Carsten Korth, Kiyotoshi Kaneko, Darlene Groth, Norbert Heye, Glenn Telling, James Mastrianni, Piero Parchi, Pierluigi Gambetti, Robert Will, James Ironside, Cornelia Heinrich, Patrick Tremblay, Stephen J. DeArmond, and Stanley B. Prusiner

- 4790 Therapeutic vaccine for acute and chronic motor neuron diseases: Implications for amyotrophic lateral sclerosis**  
D. N. Angelov, S. Waibel, O. Guntinas-Lichius, M. Lenzen, W. F. Neiss, T. L. Tomov, E. Yoles, J. Kipnis, H. Schori, A. Reuter, A. Ludolph, and M. Schwartz

- 4796 Erythrocyte-binding antigen 175 mediates invasion in *Plasmodium falciparum* utilizing sialic acid-dependent and -independent pathways**  
Manoj T. Duraisingh, Alexander G. Maier, Tony Triglia, and Alan F. Cowman

- 4802 Recombinant human erythropoietin protects the myocardium from ischemia-reperfusion injury and promotes beneficial remodeling**  
Laura Calvillo, Roberto Latini, Jan Kajstura, Annarosa Leri, Piero Anversa, Pietro Ghezzi, Monica Salio, Anthony Cerami, and Michael Brines

- 4807 Plasma membrane localization and function of the estrogen receptor  $\alpha$  variant (ER46) in human endothelial cells**  
Lei Li, M. Page Haynes, and Jeffrey R. Bender

- 4813 T cell leukemia I oncogene expression depends on the presence of Epstein-Barr virus in the virus-carrying Burkitt lymphoma lines**  
Csaba Kiss, Jun Nishikawa, Kenzo Takada, Pankaj Trivedi, George Klein, and Laszlo Szekeley

- 4819 Heterogeneous clearance rates of long-lived lymphocytes infected with HIV: Intrinsic stability predicts lifelong persistence**  
M. C. Strain, H. F. Günthard, D. V. Havlir, C. C. Ignacio, D. M. Smith, A. J. Leigh-Brown, T. R. Macaranas, R. Y. Lam, O. A. Daly, M. Fischer, M. Opravil, H. Levine, L. Bachelier, C. A. Spina, D. D. Richman, and J. K. Wong

## MICROBIOLOGY

- 4825 Herpes simplex virus 1 activates cdc2 to recruit topoisomerase II $\alpha$  for post-DNA synthesis expression of late genes**  
Sunil J. Advani, Ralph R. Weichselbaum, and Bernard Roizman

- 4831 A secreted high-affinity inhibitor of human TNF from Tanapox virus**  
Craig R. Brunetti, Mini Paulose-Murphy, Rajkumari Singh, Jing Qin, John W. Barrett, Aubry Tardivel, Pascal Schneider, Karim Essani, and Grant McFadden

## NEUROSCIENCE

- 4837 Amyloid deposition in the hippocampus and entorhinal cortex: Quantitative analysis of a transgenic mouse model**

John F. Reilly, Dora Games, Russell E. Rydel, Stephen Freedman, Dale Schenk, Warren G. Young, John H. Morrison, and Floyd E. Bloom

- 4843 Translational control of inducible nitric oxide synthase expression by arginine can explain the arginine paradox**  
Junghee Lee, Hoon Ryu, Robert J. Ferrante, Sidney M. Morris, Jr., and Rajiv R. Ratan

- 4849 Chemical synaptic activity modulates nearby electrical synapses**  
Mackenzie Smith and Alberto E. Pereda

- 4855 Retention of NMDA receptor NR2 subunits in the lumen of endoplasmic reticulum in targeted NR1 knockout mice**  
Masahiro Fukaya, Akira Kato, Chanel Lovett, Susumu Tonegawa, and Masahiko Watanabe

- 4861 Inhibition of calcineurin facilitates the induction of memory for sensitization in *Aplysia*: Requirement of mitogen-activated protein kinase**  
Shiv K. Sharma, Martha W. Bagnall, Michael A. Sutton, and Thomas J. Carew

- 4867 The melanocortin-1 receptor gene mediates female-specific mechanisms of analgesia in mice and humans**  
Jeffrey S. Mogil, Sonya G. Wilson, Elissa J. Chesler, Andrew L. Rankin, Kumar V. S. Nemmani, William R. Lariviere, M. Kristina Groce, Margaret R. Wallace, Lee Kaplan, Roland Staud, Timothy J. Ness, Toni L. Glover, Magda Stankova, Alexander Mayorov, Victor J. Hruby, Judith E. Grisel, and Roger B. Fillingim

- 4873 Neural, not gonadal, origin of brain sex differences in a gynandromorphic finch**  
Robert J. Agate, William Grisham, Juli Wade, Suzanne Mann, John Wingfield, Carolyn Schanen, Aarno Palotie, and Arthur P. Arnold

- 4879 Dichloroacetate effects on glucose and lactate oxidation by neurons and astroglia *in vitro* and on glucose utilization by brain *in vivo***  
Yoshiaki Itoh, Takanori Esaki, Kazuaki Shimoji, Michelle Cook, Mona J. Law, Elaine Kaufman, and Louis Sokoloff

- 4885 The high variance of AMPA receptor- and NMDA receptor-mediated responses at single hippocampal synapses: Evidence for multiquantal release**  
Rossella Conti and John Lisman

- 4897 Timing of neural responses in cortical organotypic slices**  
Dean V. Buonomano

## PHARMACOLOGY

- 4891 Endothelial nitric oxide synthase overexpression attenuates congestive heart failure in mice**  
Steven P. Jones, James J. M. Greer, Rien van Haperen, Dirk J. Duncker, Rini de Crom, and David J. Lefer

4897 **Timing of neural responses in cortical organotypic slices**  
Dean V. Buonomano

4903 **The G protein-coupled receptor repertoires of human and mouse**

Demetrios K. Vassilatis, John G. Hohmann, Hongkui Zeng, Fusheng Li, Jane E. Ranchalis, Marty T. Mortrud, Analisa Brown, Stephanie S. Rodriguez, John R. Weller, Abbie C. Wright, John E. Bergmann, and George A. Gaitanaris

4909 **Membrane potential fluorescence: A rapid and highly sensitive assay for nicotinic receptor channel function**

Richard W. Fitch, Yingxian Xiao, Kenneth J. Kellar, and John W. Daly

4915 **Prenatal exposure to a cannabinoid agonist produces memory deficits linked to dysfunction in hippocampal long-term potentiation and glutamate release**

Giampaolo Mereu, Mauro Fà, Luca Ferraro, Raffaele Cagiano, Tiziana Antonelli, Maria Tattoli, Veronica Ghiglieri, Sergio Tanganelli, Gian Luigi Gessa, and Vincenzo Cuomo

## PLANT BIOLOGY

4921 **Early light-induced proteins protect *Arabidopsis* from photooxidative stress**

Claire Hutin, Laurent Nussaume, Nicolae Moise, Ismaël Moya, Klaus Kloppstech, and Michel Havaux

4927 **Bacterial volatiles promote growth in *Arabidopsis***

Choong-Min Ryu, Mohamed A. Farag, Chia-Hui Hu, Munagala S. Reddy, Han-Xun Wei, Paul W. Paré, and Joseph W. Kloepper

4933 **Circadian phase-specific degradation of the F-box protein ZTL is mediated by the proteasome**

Woe-Yeon Kim, Ruishuang Geng, and David E. Somers

4939 **Combinatorial modification of multiple lignin traits in trees through multigene cotransformation**

Laigeng Li, Yihua Zhou, Xiaofei Cheng, Jiayan Sun, Jane M. Marita, John Ralph, and Vincent L. Chiang

4945 **A network of rice genes associated with stress response and seed development**

Bret Cooper, Joseph D. Clarke, Paul Budworth, Joel Kreps, Don Hutchison, Sylvia Park, Sonia Guimil, Molly Dunn, Peter Luginbühl, Cinzia Ellero, Stephen A. Goff, and Jane Glazebrook

## PSYCHOLOGY

4951 **Predicting the practice effects on the blood oxygenation level-dependent (BOLD) function of fMRI in a symbolic manipulation task**

Yulin Qin, Myeong-Ho Sohn, John R. Anderson, V. Andrew Stenger, Kate Fissell, Adam Goode, and Cameron S. Carter

## SOCIAL SCIENCES

### ANTHROPOLOGY

4957 **A reexamination of human-induced environmental change within the Lake Pátzcuaro Basin, Michoacán, Mexico**

Christopher T. Fisher, Helen P. Pollard, Isabel Israde-Alcántara, Victor H. Garduño-Monroy, and Subir K. Banerjee

→ See commentary on page 4366

### SOCIAL SCIENCES

4963 **New consumers: The influence of affluence on the environment**

Norman Myers and Jennifer Kent

## CORRECTIONS

### CELL BIOLOGY

4970 **Molecular characterization of lymphatic endothelial cells**

Simona Podgrabinska, Pascal Braun, Paula Velasco, Bryan Kloos, Michael S. Pepper, David G. Jackson, and Mihaela Skobe

### IMMUNOLOGY

4969 **Natural killer cells attack tumor cells expressing high levels of sialyl Lewis x oligosaccharides**

Chikara Ohyama, Satoru Kanto, Kazunori Kato, Osamu Nakano, Yoichi Arai, Tetsuro Kato, Shihao Chen, Michiko N. Fukuda, and Minoru Fukuda

### MEDICAL SCIENCES

4969 **Natural killer cells attack tumor cells expressing high levels of sialyl Lewis x oligosaccharides**

Chikara Ohyama, Satoru Kanto, Kazunori Kato, Osamu Nakano, Yoichi Arai, Tetsuro Kato, Shihao Chen, Michiko N. Fukuda, and Minoru Fukuda

4970 **Insulin resistance is a poor predictor of type 2 diabetes in individuals with no family history of disease**

Allison B. Goldfine, Clara Bouche, Robert A. Parker, Caroline Kim, Amy Kerivan, J. Stuart Soeldner, Blaise C. Martin, James H. Warram, and C. Ronald Kahn

xi–xiii Author Index

xiv–xvi Information for Authors

xvii Sizing Worksheet/Submission Checklist Form

xviii Copyright Assignment/Documentation Report Form

xix Classified Advertisements

# Biologic activity of cytotoxic T lymphocyte-associated antigen 4 antibody blockade in previously vaccinated metastatic melanoma and ovarian carcinoma patients

F. Stephen Hodi\*, Martin C. Mihm†, Robert J. Soiffer\*, Frank G. Haluska‡, Marcus Butler\*, Michael V. Seiden‡, Thomas Davis§, Rochele Henry-Spires\*, Suzanne MacRae\*, Ann Willman\*, Robert Padera¶, Michael T. Jaklitsch||, Sridhar Shankar\*\*, Teresa C. Chen††, Alan Korman§, James P. Allison††, and Glenn Dranoff\*§§

\*Department of Adult Oncology, Dana-Farber Cancer Institute and Department of Medicine, Brigham and Women's Hospital and Harvard Medical School, Boston, MA 02115; Departments of †Pathology and ‡Medicine, Massachusetts General Hospital and Harvard Medical School, Boston, MA 02114; §Medarex, Inc., Annandale, NJ 08801; Departments of ¶Pathology and ||Surgery, Brigham and Women's Hospital and Harvard Medical School, Boston, MA 02115; \*\*Department of Radiology, Dana-Farber Cancer Institute and Harvard Medical School, Boston, MA 02115; ††Massachusetts Eye and Ear Infirmary and Harvard Medical School, Boston, MA 02114; and §§Howard Hughes Medical Institute and Cancer Research Lab, University of California, Berkeley, CA 94720

Contributed by James P. Allison, February 19, 2003

**A large number of cancer-associated gene products evoke immune recognition, but host reactions rarely impede disease progression. The weak immunogenicity of nascent tumors contributes to this failure in host defense. Therapeutic vaccines that enhance dendritic cell presentation of cancer antigens increase specific cellular and humoral responses, thereby effectuating tumor destruction in some cases. The attenuation of T cell activation by cytotoxic T lymphocyte-associated antigen 4 (CTLA-4) further limits the potency of tumor immunity. In murine systems, the administration of antibodies that block CTLA-4 function inhibits the growth of moderately immunogenic tumors and, in combination with cancer vaccines, increases the rejection of poorly immunogenic tumors, albeit with a loss of tolerance to normal differentiation antigens. To gain a preliminary assessment of the biologic activity of antagonizing CTLA-4 function in humans, we infused a CTLA-4 blocking antibody (MDX-CTLA4) into nine previously immunized advanced cancer patients. MDX-CTLA4 stimulated extensive tumor necrosis with lymphocyte and granulocyte infiltrates in three of three metastatic melanoma patients and the reduction or stabilization of CA-125 levels in two of two metastatic ovarian carcinoma patients previously vaccinated with irradiated, autologous granulocyte-macrophage colony-stimulating factor-secreting tumor cells. MDX-CTLA4 did not elicit tumor necrosis in four of four metastatic melanoma patients previously immunized with defined melanoma antigens. No serious toxicities directly attributable to the antibody were observed, although five of seven melanoma patients developed T cell reactivity to normal melanocytes. These findings suggest that CTLA-4 antibody blockade increases tumor immunity in some previously vaccinated cancer patients.**

**T**he formulation of genetic and biochemical strategies to identify cancer antigens yielded the unexpected discovery that tumor development frequently evokes immune recognition (1, 2). Cancer-associated gene products may stimulate T, B, and natural killer T (NKT) lymphocytes, natural killer cells, and phagocytes (3–7). Although the presence of brisk T cell infiltrates in human tumors is correlated with improved clinical outcomes, host responses in most cases are insufficient to inhibit disease progression (8–12).

One mechanism that may contribute to the failure of host defense is inadequate tumor antigen presentation (13). Cancer cells typically lack the expression of costimulatory molecules necessary to prime potent T lymphocyte responses directly, and dendritic cells infiltrating established tumors generally display limited maturation (14). Under these conditions, the induced tumor-reactive T cells manifest impaired functional capabilities. One strategy to ameliorate this defect in antigen presentation involves vaccination with irradiated tumor cells engineered to

secrete granulocyte-macrophage colony-stimulating factor (GM-CSF) (15). Immunization elicits large numbers of activated CD11b<sup>+</sup> dendritic cells that express high levels of B7-1, B7-2, MHC II, and CD1d (16). These recruited cells efficiently phagocytose and process dying tumor cells, migrate to regional lymph nodes, and stimulate tumor-specific lymphocytes (17, 18). CD4<sup>+</sup> and CD8<sup>+</sup> T cells, CD1d-restricted invariant NKT cells, and antibodies mediate protective immunity (15, 16, 19, 20). A phase I clinical trial using retroviral-mediated gene transfer to engineer autologous GM-CSF-secreting melanoma cells established the ability of this vaccination scheme to enhance cancer immunity in metastatic melanoma patients (21). A second therapeutic strategy to improve tumor antigen presentation involves the loading of cancer antigens, in a variety of formulations, onto *ex vivo*-expanded dendritic cells (22). Several early-stage clinical trials have also demonstrated the ability of this vaccination scheme to increase tumor immunity (23–27).

Although a minority of patients achieved durable clinical responses in these studies, most eventually succumbed to progressive disease. One mechanism that may limit the therapeutic potency of cancer vaccines is the attenuation of T cell function by cytotoxic T lymphocyte-associated antigen 4 (CTLA-4) (28). Although the binding of B7-1 or B7-2 to CD28 provides an important costimulatory signal, the engagement of CTLA-4 by these ligands induces cell cycle arrest and diminished cytokine production (29–31). The development of a lethal lymphoproliferative disorder in young CTLA-4-deficient mice illuminates the pivotal role of CTLA-4 in immune homeostasis (32, 33). As CD4<sup>+</sup>, but not CD8<sup>+</sup>, T cell depletion reduces the autoimmune disease in these mice, the activities of CTLA-4 are essential for normal helper T cell regulation (34).

In contrast to the severe pathology characteristic of CTLA-4-deficient mice, transient CTLA-4 antibody blockade enhances antigen-specific T cell responses with limited toxicities. The injection of anti-CTLA-4 antibodies stimulates the rejection of moderately immunogenic murine tumors, and this activity may be potentiated with chemotherapy (35–38). Although CTLA-4 antibody blockade alone elicits minimal effects against poorly immunogenic tumors, concurrent vaccination with irradiated, GM-CSF-secreting tumor cells is highly efficacious in the B16 melanoma, SM1 breast carcinoma, and transgenic adenocarcinoma of the mouse prostate (TRAMP) carcinoma models (39–41). Cytotoxic T cells are critical for tumor destruction, but the augmented anticancer response may be associated with the

Abbreviations: CTLA-4, cytotoxic T lymphocyte-associated antigen 4; GM-CSF, granulocyte-macrophage colony-stimulating factor.

§§To whom correspondence should be addressed. E-mail: glenn.dranoff@dfci.harvard.edu.

**Table 1. Patient characteristics**

| Patient | Age | Diagnosis                | Treatment 1            | Recurrence                 | Treatment 2             | Treatment 3        | Treatment 4                                     | MDX-CTLA-4    | Metastases                     |
|---------|-----|--------------------------|------------------------|----------------------------|-------------------------|--------------------|-------------------------------------------------|---------------|--------------------------------|
| 1       | 43  | Skin (MM)<br>1995        | Surgery                | Parotid, lung<br>1998      | GVAX<br>7/98–2/99       | Chemo<br>2/99–9/99 | PS341<br>4/00–6/00                              | 1/01          | CNS, lung,<br>abdomen, skin    |
| 2       | 56  | LN (MM)<br>1992          | Surgery, $\alpha$ -IFN | SC, perirenal,<br>LN, 1998 | GVAX<br>6/98–11/99      | —                  | —                                               | 1/01          | LN, bone, perirenal            |
| 3       | 43  | LN (MM)<br>1997          | Surgery, $\alpha$ -IFN | LN, intestine<br>1998      | Surgery 12/98           | DC<br>4/00–9/00    | —                                               | 11/00         | LN                             |
| 4       | 58  | Skin (MM)<br>1998        | Surgery, XRT           | Skin, lung<br>2000         | DC 5/00–8/00            | XRT 8/00           | —                                               | 1/01          | CNS, lung                      |
| 5       | 49  | Skin, LN<br>(MM)<br>1998 | Surgery, $\alpha$ -IFN | SC 2000                    | DC 11/00–2/00           | —                  | —                                               | 4/01          | SC, lung, liver, LN            |
| 6       | 52  | SC (MM)<br>1997          | Surgery, GM2           | LN, lung<br>2000           | gp100<br>12/00–3/01     | Chemo<br>4/01–6/01 | —                                               | 7/01          | Lung, LN                       |
| 7       | 31  | Skin (MM)<br>1994        | Surgery                | LN, lung, SC,<br>CNS, 1996 | Surgery, chemo,<br>8/96 | GVAX<br>7/98–10/98 | Chemo, XRT<br>1/99–6/99,<br>2/01–10/01          | 9/02          | SC                             |
| 8       | 38  | Pelvis (OV)<br>1998      | Surgery,<br>chemo      | Lung,<br>pelvis<br>7/99    | Chemo<br>8/99–12/99     | MUC-1<br>4/00–6/00 | Chemo, GVAX,<br>CI-1033,<br>6/00, 4/01,<br>2/02 | 6/02<br>10/02 | Lung, pelvis,<br>retroperitone |
| 9       | 65  | PER (OV)<br>1999         | Chemo                  | PER 2001                   | Chemo<br>9/01–12/01     | Chemo<br>2/02–5/02 | GVAX<br>6/02–8/02                               | 9/02          | PER                            |

MM, malignant melanoma; OV, ovarian carcinoma; SC, subcutaneous tissue; LN, lymph node; PER, peritoneum; GM2, ganglioside + QS-21; GVAX, irradiated, autologous tumor cells engineered to secrete GM-CSF; DC, dendritic cells engineered to express gp100 and MART-1; gp100, peptide plus IL-2; MUC-1, MUC-1 conjugated to KLH plus QS-21; XRT, radiation therapy; PS341, proteasome inhibitor; CI-1033, epidermal growth factor kinase inhibitor.

loss of tolerance to normal differentiation antigens, culminating in autoimmune vitiligo or prostatitis (42).

To gain a preliminary assessment of the biologic activity of antagonizing CTLA-4 function in humans, we administered the CTLA-4 blocking antibody MDX-CTLA-4 to nine previously vaccinated metastatic melanoma or ovarian carcinoma patients.

## Materials and Methods

**Clinical Protocols.** The phase I studies of vaccination with irradiated, autologous melanoma or ovarian carcinoma cells engineered to secrete GM-CSF by adenoviral-mediated gene transfer will be reported elsewhere. The phase I study of vaccination with autologous dendritic cells engineered to express gp100 and MART-1 by adenoviral-mediated gene transfer will also be presented separately. The studies of vaccination with GM2 ganglioside admixed with QS-21 and immunization with a modified gp100 peptide plus IL-2 have been described (43, 44).

Patients 1–6 were enrolled in the Medarex-sponsored phase I trial MDX-CTLA-4-02 that was approved by the Dana-Farber Partners Cancer Care Institutional Review Board. Patients were eligible for this study if they had surgically unresectable stage III or stage IV malignant melanoma, disease progression, a life expectancy of at least 12 weeks, adequate end organ function, stable analgesic therapy, and a Karnofsky performance status of at least 60%. Patients were excluded if they used corticosteroids or had a second malignancy other than treated nonmelanoma skin cancer or superficial bladder cancer, autoimmune disease, active infection, or hypersensitivity to kanamycin. Patients 7–9 were treated on a Dana-Farber Partners Cancer Care-initiated trial of MDX-CTLA-4 infusion for metastatic melanoma, metastatic ovarian carcinoma, metastatic nonsmall cell lung carcinoma, or acute myelogenous leukemia patients previously vaccinated with irradiated, autologous, GM-CSF-secreting tumor cells. (The entire study, which will involve 16 patients, will be reported separately after its completion.) All patients provided written informed consent before enrollment in each clinical trial.

MDX-CTLA-4 is a human IgG1 antibody obtained from transgenic HuMAb mice, strain HC2/Kco7 (Medarex), immunized with the extracellular domain of CTLA-4. The antibody blocks binding of B7-1 Ig and B7-2 Ig to CTLA-4. MDX-CTLA-4 was drawn through a 0.22- $\mu$ m filter and diluted in normal saline to a concentration of 2.5 mg/ml for administration. A test dose of 0.2 mg in 10 ml of normal saline was infused i.v. over 10 min to identify potential hypersensitivity reactions. The remainder of the 3 mg/kg MDX-CTLA-4 single dose was then delivered over 90 min with a volumetric pump. Patients were seen three times daily, four times weekly, and at monthly intervals thereafter for routine clinical, laboratory, and radiographic evaluation.

**Pathology.** Tissues were fixed in 10% neutral buffered formalin, processed routinely, and embedded in paraffin. Immunohistochemistry was performed by using standard techniques with monoclonal antibodies to CD4, CD8, CD20, and Ig- $\kappa$ .

## Results

**Patient Characteristics.** Seven metastatic melanoma and two ovarian carcinoma patients received MDX-CTLA-4 therapy between November 2000 and October 2002 (Table 1). The melanoma patients were all males with a median age of 49 years (range of 31–58 years). The average interval between the initial diagnosis of melanoma and study entry was 5 years (range of 3–9 years). Four patients received adjuvant therapies for early-stage disease ( $\alpha$ -IFN,  $n = 3$ ; vaccination with GM2 ganglioside admixed with QS-21,  $n = 1$ ; radiation,  $n = 1$ ). Nonimmunologic treatments for metastatic disease before enrollment were surgery ( $n = 4$ ), radiation therapy ( $n = 2$ ), chemotherapy ( $n = 3$ ), and proteasome inhibitor ( $n = 1$ ). The two ovarian carcinoma patients received multiple chemotherapies for relapsing disease throughout the 3–4 years before study enrollment.

All nine subjects participated in phase I vaccine studies for metastatic disease before entry into the MDX-CTLA-4 trial. Three melanoma and both ovarian carcinoma patients were immunized with irradiated, autologous tumor cells engineered to

**Table 2. Biologic activity of CTLA-4 antibody blockade**

| Patient | Prior vaccine | Autoantibodies             | $\Delta$ Neut | Melanocyte reactivity | Antitumor effects                                                  |
|---------|---------------|----------------------------|---------------|-----------------------|--------------------------------------------------------------------|
| 1       | GVAX          | None                       | 2             | Skin                  | Extensive hemorrhagic necrosis with granulocytes and lymphocytes   |
| 2       | GVAX          | ANA 1:160                  | 4             | Skin retina           | Extensive necrosis with granulocytes and lymphocytes; vasculopathy |
| 3       | DC            | ANA 1:80, $\alpha$ -TG 212 | 3             | Skin                  | CD8 <sup>+</sup> T cell infiltrate; no tumor necrosis              |
| 4       | DC            | RF 28                      | 0             | Skin                  | CD8 <sup>+</sup> T cell infiltrate; no tumor necrosis              |
| 5       | DC            | None                       | 2.5           | Skin                  | No tumor necrosis; absent infiltrate                               |
| 6       | GM2, gp100    | None                       | 0             | No                    | Not done                                                           |
| 7       | GVAX          | None                       | 0             | No                    | Extensive necrosis with granulocytes and lymphocytes; vasculopathy |
| 8       | MUC-1, GVAX   | None                       | 0             | No                    | CA-125 reduction                                                   |
| 9       | GVAX          | ANA 1:160                  | 0             | No                    | CA-125 stabilization                                               |

GVAX, irradiated, autologous tumor cells engineered to secrete GM-CSF; DC, dendritic cells engineered to express gp100 and MART-1; gp100, peptide plus IL-2; MUC-1, MUC-1 conjugated to KLH plus QS-21; ANA, antinuclear antibodies;  $\alpha$ -TG, antithyroglobulin antibodies; RF, rheumatoid factor;  $\Delta$  Neut, fold increase in neutrophils.

secrete GM-CSF by adenoviral-mediated gene transfer (patient 8 also received a MUC-1 vaccine). Three melanoma patients were immunized with autologous dendritic cells engineered to express gp100 and MART-1 by adenoviral-mediated gene transfer. One melanoma patient was vaccinated with a modified gp100 peptide and high-dose IL-2.

**MDX-CTLA-4 Toxicities.** A single dose of the human MDX-CTLA-4 antibody (3 mg/kg) was administered i.v. over 1.5 h. There was one acute hypersensitivity reaction characterized by mild hypotension and nausea during the infusion; this was easily controlled with antihistamines, and the treatment was completed uneventfully. Five patients developed transient grade 1–2 constitutional symptoms consisting of myalgias, arthralgias, anorexia, fatigue, nasal congestion, and nonproductive cough 2–7 days after the infusion; in one case, the syndrome recurred intermittently for several months. One patient with hepatic metastases manifested a transient grade 3 liver function test abnormality. Otherwise, there were no significant renal, pulmonary, cardiac, hematologic, gastrointestinal, or neurologic toxicities directly attributable to the antibody.

**Autoimmune Reactions.** MDX-CTLA-4 stimulated low titers of autoantibodies that persisted for 1–2 months without clinical evidence of autoimmune disease in four patients (Table 2). These included antinuclear antibodies (speckled pattern at 1:80 or 1:160 dilutions), antithyroglobulin antibodies (212, normal <60), and rheumatoid factors (28, normal <15). Four subjects mounted short-lived (24 h to 2 weeks) increases in circulating neutrophil counts (2- to 4-fold elevations).

All of the melanoma patients developed an asymptomatic, grade 1 reticular and erythematous rash on the trunk and extremities between 3 days and 3 weeks after MDX-CTLA-4 infusion (Fig. 1A). Punch biopsies of the skin in five of the seven subjects revealed prominent peri-vascular T cell infiltrates in the superficial dermis that extended into the epidermis (Fig. 1B). CD4<sup>+</sup> and CD8<sup>+</sup> T cells were found apposed to dying melanocytes in these sections (Fig. 1C and D), although vitiligo was not clinically evident. Mild, focal hypopigmentation of the retinal pigmented epithelium was also detected by ophthalmologic examination in one patient, but this was not associated with a change in visual acuity. One ovarian carcinoma patient (no. 8) developed a transient erythematous rash on the face and trunk 2 weeks after infusion. Skin biopsy demonstrated perivascular T cell infiltrates in the superficial dermis, but no host reactivity toward melanocytes (not shown). Changes similar to these may be observed in hypersensitivity responses or some connective tissue diseases.

**Antitumor Effects.** MDX-CTLA-4 elicited extensive tumor necrosis with immune infiltrates in the three melanoma patients previously vaccinated with irradiated, autologous GM-CSF-secreting tumor cells. Patient 1 harbored metastases in the CNS, lungs, abdomen, and soft tissues at study entry. One month after MDX-CTLA-4 administration, a distinct change in clinical status was noted. A s.c. nodule became acutely inflamed (Fig. 2A), and facial twitching, slurred speech, impaired coordination, and weakness developed shortly thereafter. Magnetic resonance imaging revealed an increase in the gadolinium uptake of multiple brain lesions, suggesting an alteration in blood flow. Several cord compressions were detected in the cervical and thoracic spine, and large visceral metastases were present in the abdomen and lung. The patient deteriorated rapidly and died 6 days later, likely from CNS disease. Unexpectedly, marked hemorrhagic tumor necrosis was found at gross autopsy in numerous brain, epidural, and visceral metastases (Fig. 2B and C). Histopathologic examination disclosed extensive tumor destruction (at least 90%) with hemorrhage (Fig. 2D and E). While a rim of viable tumor cells persisted in each lesion, this was accompanied by a granulocyte and lymphocyte reaction (Fig. 2F).

Patient 2 manifested recurrent episodes of grade 2 constitutional symptoms beginning 1 month after MDX-CTLA-4 infusion. A biopsy of a mediastinal mass revealed extensive tumor necrosis with lymphocyte and granulocyte infiltrates (Fig. 3A




**Fig. 1.** MDX-CTLA-4 stimulated melanocyte immune recognition. (A) Reticular erythematous rash. (B) Perivascular lymphocyte infiltrate extending into epidermis with interface dermatitis. (C) CD4<sup>+</sup> T cells apposed to dying melanocytes. (D) CD8<sup>+</sup> T cells apposed to dying melanocytes. (Magnification:  $\times 125$ , B;  $\times 250$ , C and D.)




**Fig. 2.** MDX-CTLA-4 induced hemorrhagic tumor necrosis in vaccinated patient 1. (A) Inflamed s.c. nodule. (B) Necrotic brain metastasis. (C) Necrotic lung metastasis. (D and E) Hemorrhagic tumor necrosis. (F) Rim of viable tumor with granulocytes and lymphocytes. (Magnification:  $\times 250$ , D–F.)

and B). Neutrophils were more prominent than eosinophils in the reaction. Immunohistochemistry disclosed the presence of CD4<sup>+</sup> and CD8<sup>+</sup> T cells and CD20<sup>+</sup> B lymphocytes producing Ig (Fig. 3 C–E). The lesion was completely resected 2 months later, and pathologic analysis demonstrated dense fibrosis, ex-




**Fig. 3.** MDX-CTLA-4 induced extensive tumor necrosis in vaccinated patient 2. (A and B) Tumor necrosis with granulocytes and lymphocytes. (C) CD4<sup>+</sup> T cells. (D) CD8<sup>+</sup> T cells. (E) CD20<sup>+</sup> B cells. (F) Vasculopathy with perivascular and intramural lymphoid infiltrates associated with luminal thrombosis. (Magnification:  $\times 125$ , A;  $\times 250$ , B–F.)




**Fig. 4.** MDX-CTLA-4 induced CD8<sup>+</sup> T cell infiltrates but no tumor necrosis in vaccinated patients 3 and 4. (A) Lymphocyte infiltrate without tumor destruction. (B) CD8<sup>+</sup> T cells. (C) CD4<sup>+</sup> T cells. (D) CD20<sup>+</sup> B cells. (Magnification:  $\times 250$ , A and B;  $\times 500$ , C and D.)

tensive necrosis, and an ongoing lymphocyte and granulocyte response (not shown). A vasculopathy characterized by a circumferential lymphoid infiltrate in the wall of an occluded blood vessel was also noted (Fig. 3F); tumor necrosis appeared spatially related to the vessel damage. Three months afterward, a zygomatic arch metastasis recurred. Chemotherapy with cisplatin and dacarbazine induced substantial tumor regression that persisted for 18 months.

Patient 7 developed inflammation in a large s.c. mass 3 weeks after MDX-CTLA-4 infusion. The lesion was excised at 2 months, and pathologic examination similarly revealed extensive tumor necrosis and fibrosis with lymphocyte and granulocyte infiltrates. Moreover, perivascular lymphoid aggregates and infiltration of the vessel wall associated with thrombosis was again observed (data not shown).

CTLA-4 antibody blockade evoked less significant antitumor effects in the four melanoma patients previously immunized with defined melanosomal antigens. Patient 3 underwent a resection of an enlarging mediastinal mass 7 months after MDX-CTLA-4 infusion. Pathologic study revealed a dense lymphocyte infiltrate without tumor necrosis (Fig. 4A). Immunohistochemistry disclosed the presence of CD8<sup>+</sup> T, but not CD4<sup>+</sup> T or CD20<sup>+</sup> B, cells (Fig. 4 B–D). Although a brief period of stable disease followed treatment with cisplatin and dacarbazine, brain metastases developed shortly thereafter. Patient 4 showed a comparable CD8<sup>+</sup> T cell infiltrate without tumor necrosis in a lymph node metastasis resected 2 months after antibody administration. Subsequent chemotherapy similarly did not achieve a response, and the patient died 10 months after study entry. Patient 5 failed to develop lymphoid infiltrates or tumor necrosis in a s.c. metastasis resected 2 months after MDX-CTLA-4 administration (data not shown); follow-up chemotherapy was ineffective. Lastly, although patient 6 did not undergo a biopsy after MDX-CTLA-4 infusion, his clinical course was characterized by steady tumor progression that proved unresponsive to chemotherapy.

Although tumor biopsies could not be obtained in the two ovarian carcinoma patients after MDX-CTLA-4 infusion, the antibody elicited clear changes in blood CA-125 levels. This glycoprotein antigen is shed from the surface of ovarian carcinoma cells, thereby serving as a useful marker of disease status (45). Patient 8 showed a 43% reduction in CA-125 values (from 230 to 132) beginning 2 months after antibody infusion; although this response was not maintained, a second infusion of MDX-CTLA-4 stabilized CA-125 levels for 2 months (Fig. 5A). Patient




**Fig. 5.** MDX-CTLA-4 induced alterations in the circulating ovarian carcinoma tumor marker CA-125. (A) Patient 8. (B) Patient 9. Arrows indicate MDX-CTLA-4 infusions.

9 achieved a plateau in CA-125 values 1 month after antibody infusion (concomitant with a reduction in ascites and pain), despite rapidly rising levels before treatment (Fig. 5B).

## Discussion

This phase I clinical investigation was undertaken in an effort to obtain a preliminary assessment of the biologic activity and toxicity of MDX-CTLA-4 in previously vaccinated metastatic melanoma and ovarian carcinoma patients. The study was motivated by compelling preclinical data indicating that the combination of CTLA-4 antibody blockade and cancer vaccination stimulated greater levels of antitumor immunity than either approach alone. Because the combination treatment also provoked a loss of tolerance to normal differentiation antigens, the risk of serious toxicities to patients was of some concern. Hence, we initially elected to administer CTLA-4 antibody blockade to previously vaccinated cancer patients.

Our initial results suggest that a single infusion of MDX-CTLA-4 may be safely delivered in this clinical setting. The generation of low titers of autoantibodies shows that the therapy may at least partially compromise systemic tolerance, but no evidence for autoimmune disease was noted. The melanoma patients developed a reticular and erythematous rash caused by perivascular lymphoid aggregates in the superficial dermis that extended into the epidermis. Both CD4<sup>+</sup> and CD8<sup>+</sup> T cells were juxtaposed with dying melanocytes in the skin, and one patient manifested focal hypopigmentation of the retinal pigmented epithelium as well. Although these findings demonstrate a loss of tolerance to melanocyte differentiation antigens, neither vitiligo nor alterations in visual acuity ensued, likely reflecting incomplete melanocyte destruction. Although the preclinical studies delineated a critical role for CD8<sup>+</sup> T cells in mediating depigmentation (42), the data presented here suggest that CD4<sup>+</sup> T cells may also contribute to melanocyte recognition.

MDX-CTLA-4 elicited antitumor effects in five of five patients previously immunized with irradiated, autologous GM-CSF-

secreting tumor cells, whereas minimal tumor destruction was noted in the four patients previously immunized with defined melanosomal antigens. These preliminary findings raise the possibility that specific characteristics of preexisting tumor immunity may influence the response to subsequent CTLA-4 antibody blockade. The results may also be consistent with experiments showing that CTLA-4 antibody blockade elicits potent antitumor effects against moderately immunogenic, but not poorly immunogenic, murine tumors (35–41).

The mechanisms underlying the ability of CTLA-4 antibody blockade to increase tumor immunity remain to be clarified. Recent investigations reveal that CTLA-4 traffics to the immunologic synapse in response to T cell activation, thereby delivering an attenuating signal (46, 47). In immunized patients, tumor-reactive memory or effector T cells encountering antigen-loaded dendritic cells in the periphery or secondary lymphoid tissues may be the targets for CTLA-4 antibody blockade. Alternatively, MDX-CTLA-4 may modulate the activities of regulatory T cells that constitutively express surface CTLA-4 (48). In either or both cases, the relative importance of CTLA-4 blockade in augmenting effector T cell function versus modifying the affinity and/or breadth of T cell tumor recognition remains to be delineated.

Pathologic analysis of the metastases resected after MDX-CTLA-4 infusion disclosed several pathways that contributed to tumor destruction. The autopsy of patient 1 revealed striking hemorrhagic necrosis in all of the lesions examined. Tumor blood vessels were severely damaged in these masses, resulting in extensive ischemic necrosis and some bleeding. A rim of viable tumor was still present, but it was infiltrated with granulocytes and lymphocytes. Similar pathologic features were originally described in response to Coley's toxins (49), and tumor necrosis factor was later identified as one mediator of the reaction (50). Although the mechanisms underlying hemorrhagic necrosis are not yet fully defined, both soluble factors and leukocytes participate in vessel destruction (51). Indeed, a striking circumferential lymphoid infiltrate was detected in occluded tumor blood vessels in patients 2 and 7. As this mechanism of tumor destruction does not involve a rapid reduction in tumor volume, MDX-CTLA-4 may not prove clinically useful, however, in the setting of large CNS metastases.

An unexpected finding was the prominent effect of CTLA-4 antibody blockade on neutrophil responses. MDX-CTLA-4 induced significant increases in circulating neutrophils, and robust neutrophil infiltrates were associated with tumor necrosis. A primary role for neutrophils in mediating tumor destruction was previously suggested by experiments characterizing the host reaction to tumor cells engineered to secrete G-CSF (52). As T cells from CTLA-4-deficient mice show enhanced secretion of multiple cytokines including GM-CSF (33, 53), the recruitment of neutrophils may be secondary to T cell activation.

The serial biopsies of the mediastinal mass from patient 2 suggested the possibility of the evolution of a coordinated cellular and humoral antitumor response. Immunohistochemistry disclosed CD4<sup>+</sup> and CD8<sup>+</sup> T cells and CD20<sup>+</sup> B cells producing Ig. Although the preclinical studies underscored the importance of cytotoxic T cells in effectuating tumor destruction (42), these results suggest that a broader lymphocyte reaction may be involved. Indeed, CD8<sup>+</sup> T cells (without CD4<sup>+</sup> and CD20<sup>+</sup> lymphocytes) were detected in the metastases of two patients previously immunized with melanosomal antigens; however, neither lesion manifested tumor necrosis. More detailed investigations of the functions of helper T and B cells in the antitumor effects of CTLA-4 antibody blockade are warranted.

Overall, the findings reported here should stimulate more extensive clinical evaluation of the combination of tumor vaccines and MDX-CTLA-4. Although the preclinical experiments tested concurrent administration, this study illustrates that the temporal separation of immunization and antibody blockade

may also elicit important antitumor effects. Because our previous reports of GM-CSF-secreting melanoma vaccines similarly revealed the induction of a vasculopathy and of granulocyte, CD4<sup>+</sup>, CD8<sup>+</sup>, and CD20<sup>+</sup> lymphocyte infiltrates effectuating extensive tumor necrosis and fibrosis (21, 54), the current results suggest that MDX-CTLA-4 may amplify a long-lived memory response in patients (55, 56). Future comparison of the relative toxicity and immunogenicity of concurrent versus sequential combination therapy should provide a deeper understanding of the mechanisms limiting effective tumor immunity.

We thank the Connell-O'Reilly Laboratory for excellent processing of patient material and Christine Sheehan and Esther Brisson (Albany Medical College, Albany, NY) for excellent help with the histologic specimens. This study was supported by the Berlex Oncology Foundation, National Institutes of Health Grants CA78880 (to F.S.H.), CA74886, and CA39542 (to G.D.), the Leukemia and Lymphoma Society Score Award in Acute Myeloid Leukemia (to G.D.), the Cancer Research Institute/Partridge Foundation Clinical Investigator Award, the Cancer Research Institute Melanoma Initiative (to G.D.), and Medarex. G.D. and R.J.S. are Clinical Scholars of the Leukemia and Lymphoma Society.

- Boon, T. & van der Bruggen, P. (1996) *J. Exp. Med.* **183**, 725–729.
- Old, L. & Chen, Y.-T. (1998) *J. Exp. Med.* **187**, 1163–1167.
- Sahin, U., Tureci, O., Schmitt, H., Cochlovius, B., Johannes, T., Schmits, R., Stenner, F., Luo, G. R., Schobert, I. & Pfreundschuh, M. (1995) *Proc. Natl. Acad. Sci. USA* **92**, 11810–11813.
- Zeng, G., Wang, X., Robbins, P., Rosenberg, S. & Wang, R.-F. (2001) *Proc. Natl. Acad. Sci. USA* **98**, 3964–3969.
- Jäger, E., Nagata, Y., Gnjatic, S., Wada, H., Stockert, E., Karbach, J., Dunbar, P., Lee, S., Jungbluth, A., Jäger, D., et al. (2000) *Proc. Natl. Acad. Sci. USA* **97**, 4760–4765.
- Bauer, S., Groh, V., Wu, J., Steinle, A., Phillips, J. H., Lanier, L. L. & Spies, T. (1999) *Science* **285**, 727–729.
- Groh, V., Rhinehart, R., Secrist, H., Bauer, S., Grabstein, K. H. & Spies, T. (1999) *Proc. Natl. Acad. Sci. USA* **96**, 6879–6884.
- Clark, W., Elder, D., Guerry, D., Braitman, L., Trock, B., Schultz, D., Synnestvedt, M. & Halpern, A. (1989) *J. Natl. Cancer Inst.* **81**, 1893–1904.
- Clemente, C., Mihm, M., Bufalino, R., Zurrida, S., Collini, P. & Cascinelli, N. (1996) *Cancer (Philadelphia)* **77**, 1303–1310.
- Mihm, M., Clemente, C. & Cascinelli, N. (1996) *Lab. Invest.* **74**, 43–47.
- Naito, Y., Saito, K., Shiiba, K., Ohuchi, A., Saigenji, K., Nagura, H. & Ohtani, H. (1998) *Cancer Res.* **58**, 3491–3494.
- Nakano, O., Sato, M., Naito, Y., Suzuki, K., Orikasa, S., Aizawa, M., Suzuki, Y., Shintaku, I., Nagura, H. & Ohtani, H. (2001) *Cancer Res.* **61**, 5132–5136.
- Banchereau, J. & Steinman, R. (1998) *Nature* **392**, 245–252.
- Bell, D., Chomarat, P., Broyles, D., Netto, G., Harb, G., Lebecque, S., Valladeau, J., Davoust, J., Palucka, K. & Banchereau, J. (1999) *J. Exp. Med.* **190**, 1417–1425.
- Dranoff, G., Jaffee, E., Lazenby, A., Golumbek, P., Levitsky, H., Brose, K., Jackson, V., Hamada, H., Pardoll, D. & Mulligan, R. C. (1993) *Proc. Natl. Acad. Sci. USA* **90**, 3539–3543.
- Mach, N., Gillesen, S., Wilson, S. B., Sheehan, C., Mihm, M. & Dranoff, G. (2000) *Cancer Res.* **60**, 3239–3246.
- Huang, A. Y., Golumbek, P., Ahmadzadeh, M., Jaffee, E., Pardoll, D. & Levitsky, H. (1994) *Science* **264**, 961–965.
- Shen, Z., Reznikoff, G., Dranoff, G. & Rock, K. (1997) *J. Immunol.* **158**, 2723–2730.
- Hung, K., Hayashi, R., Lafond-Walker, A., Lowenstein, C., Pardoll, H. & Levitsky, H. (1998) *J. Exp. Med.* **188**, 2357–2368.
- Reilly, R., Machiels, J.-P., Emens, L., Ercolini, A., Okoye, F., Lei, R., Weintraub, D. & Jaffee, E. (2001) *Cancer Res.* **61**, 880–883.
- Soiffer, R., Lynch, T., Mihm, M., Jung, K., Rhuda, C., Schmollinger, J., Hodi, F., Lieber, L., Lam, P., Mentzer, S., et al. (1998) *Proc. Natl. Acad. Sci. USA* **95**, 13141–13146.
- Young, J. W. & Inaba, K. (1996) *J. Exp. Med.* **183**, 7–11.
- Hsu, F., Benike, C., Fagnoni, F., Liles, T., Czerwinski, D., Taidi, B., Engleman, E. & Levy, R. (1996) *Nat. Med.* **2**, 52–58.
- Nestle, F., Alijagic, S., Gilliet, M., Sun, Y., Grabbe, S., Dummer, R., Burg, G. & Schadendorf, D. (1998) *Nat. Med.* **4**, 328–332.
- Banchereau, J., Palucka, A. K., Dhodapkar, M., Burkeholder, S., Taquet, N., Rolland, A., Taquet, S., Coquery, S., Wittkowski, K. M., Bhardwaj, N., et al. (2001) *Cancer Res.* **61**, 6451–6458.
- Heiser, A., Coleman, D., Dannull, J., Yancey, D., Maurice, M. A., Lallas, C. D., Dahm, P., Niedzwiecki, D., Gilboa, E. & Vieweg, J. (2002) *J. Clin. Invest.* **109**, 409–417.
- Schuler-Thurner, B., Schultz, E. S., Berger, T. G., Weinlich, G., Ebner, S., Woerl, P., Bender, A., Feuerstein, B., Fritsch, P. O., Romani, N. & Schuler, G. (2002) *J. Exp. Med.* **195**, 1279–1288.
- Chambers, C. A., Kuhns, M. S., Egen, J. G. & Allison, J. P. (2001) *Annu. Rev. Immunol.* **19**, 565–594.
- Thompson, C. B. & Allison, J. P. (1997) *Immunity* **7**, 445–450.
- Doyle, A. M., Mullen, A. C., Villarino, A. V., Hutchins, A. S., High, F. A., Lee, H. W., Thompson, C. B. & Reiner, S. L. (2001) *J. Exp. Med.* **194**, 893–902.
- Salomon, B. & Bluestone, J. A. (2001) *Annu. Rev. Immunol.* **19**, 225–252.
- Waterhouse, P., Penninger, J. M., Timms, E., Wakeham, A., Shahinian, A., Lee, K. P., Thompson, C. B., Griesser, H. & Mak, T. W. (1995) *Science* **270**, 985–988.
- Tivol, E. A., Borriello, F., Schweitzer, A. N., Lynch, W. P., Bluestone, J. A. & Sharpe, A. H. (1995) *Immunity* **3**, 541–547.
- Chambers, C. A., Sullivan, T. J. & Allison, J. P. (1997) *Immunity* **7**, 885–895.
- Leach, D. R., Krummel, M. F. & Allison, J. P. (1996) *Science* **271**, 1734–1736.
- Yang, Y. F., Zou, J. P., Mu, J., Wijesuriya, R., Ono, S., Walunas, T., Bluestone, J., Fujiwara, H. & Hamaoka, T. (1997) *Cancer Res.* **57**, 4036–4041.
- Kwon, E. D., Hurwitz, A. A., Foster, B. A., Madias, C., Feldhaus, A. L., Greenberg, N. M., Burg, M. B. & Allison, J. P. (1997) *Proc. Natl. Acad. Sci. USA* **94**, 8099–8103.
- Mokyr, M. B., Kalinichenko, T., Gorelik, L. & Bluestone, J. A. (1998) *Cancer Res.* **58**, 5301–5304.
- van Elsas, A., Hurwitz, A. & Allison, J. (1999) *J. Exp. Med.* **190**, 355–366.
- Hurwitz, A., Yu, T., Leach, D. & Allison, J. (1998) *Proc. Natl. Acad. Sci. USA* **95**, 10067–10071.
- Hurwitz, A. A., Foster, B. A., Kwon, E. D., Truong, T., Choi, E. M., Greenberg, N. M., Burg, M. B. & Allison, J. P. (2000) *Cancer Res.* **60**, 2444–2448.
- van Elsas, A., Suttmoller, R. P., Hurwitz, A. A., Ziskin, J., Villasenor, J., Medema, J. P., Overwijk, W. W., Restifo, N. P., Melief, C. J., Offringa, R. & Allison, J. P. (2001) *J. Exp. Med.* **194**, 481–489.
- Livingston, P., Wong, G., Adluri, S., Tao, Y., Padavan, M., Parente, R., Hanlon, C., Calves, M., Helling, F., Ritter, G., et al. (1994) *J. Clin. Oncol.* **12**, 1036–1044.
- Rosenberg, S., Yang, J., Schwartzentruber, D., Hwu, P., Marincola, F., Topalian, S., Restifo, N., Dudley, M., Schwarz, S., Spiess, P., et al. (1998) *Nat. Med.* **4**, 321–327.
- Jacobs, I. (1994) *Gynecol. Oncol.* **55**, S22–S27.
- Egen, J. G. & Allison, J. P. (2002) *Immunity* **16**, 23–235.
- Darlington, P. J., Baroja, M. L., Chau, T. A., Siu, E., Ling, V., Carreno, B. M. & Madrenas, J. (2002) *J. Exp. Med.* **195**, 1337–1347.
- Shevach, E. M., McHugh, R. S., Piccirillo, C. A. & Thornton, A. M. (2001) *Immunol. Rev.* **182**, 58–67.
- Nauts, H., Fowler, G. & Bogatko, F. (1953) *Acta Med. Scand.* **5**–103.
- Old, L. J. (1985) *Science* **230**, 630–632.
- Mach, N. & Dranoff, G. (2000) *Curr. Opin. Immunol.* **12**, 571–575.
- Colombo, M. P., Ferrari, G., Stoppacciaro, A., Parenza, M., Rodolfo, M., Mavillo, F. & Parmiani, G. (1991) *J. Exp. Med.* **173**, 889–897.
- Khattry, R., Auger, J. A., Griffin, M. D., Sharpe, A. H. & Bluestone, J. A. (1999) *J. Immunol.* **162**, 5784–5791.
- Hodi, F. S., Schmollinger, J. C., Soiffer, R. J., Salgia, R., Lynch, T., Ritz, J., Alyea, E. P., Yang, J. C., Neuberg, D., Mihm, M. & Dranoff, G. (2002) *Proc. Natl. Acad. Sci. USA* **99**, 6919–6924.
- Metz, D. P., Farber, D. L., Taylor, T. & Bottomly, K. (1998) *J. Immunol.* **161**, 5855–5861.
- Chambers, C. A., Kuhns, M. S. & Allison, J. P. (1999) *Proc. Natl. Acad. Sci. USA* **96**, 8603–8608.